

18 June 2026

Oncology Breast Cancer Treatments

1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole): 0
- Abemaciclib + Fulvestrant: <5
- Alpelisib + Fulvestrant: 0
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only: <5
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel: 6
- Atezolizumab: 0
- Capivasertib: 0
- Capecitabine as a single agent: 0
- Carboplatin + Paclitaxel: 0
- Elacestrant: 0
- Eribulin as a single agent or in combination: <5
- Everolimus + Exemestane: 0
- Fulvestrant as a single agent: 12
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole): 0
- Palbociclib + Fulvestrant: <5
- Parp Inhibitors (Olaparib/Talazoparib): <5
- Pembrolizumab Monotherapy: 0
- Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide: 0
- Carboplatin + Paclitaxel + Pembrolizumab: 0
- Pertuzumab (Perjeta) + Trastuzumab (Herceptin): 0
- Phesgo (Pertuzumab + Trastuzumab in a single injection): 7
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole): 0
- Ribociclib + Fulvestrant: <5
- Sacituzumab Govitecan: <5
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent: 17
- Trastuzumab deruxtecan (Enhertu): 5
- Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel: 14
- Trastuzumab emtansine (Kadcyla): 8
- Any other active systemic anti-cancer therapy
 - Atez Nab-Pac: <5
 - Capecit(Pal): 23
 - Capi&Fulv: <5
 - DCPhesgo: <5
 - Docetaxel/Cyclo: <5

18 June 2026

- D-Phesgo: <5
- EC-D: 14
- ECDPhesgo: 10
- ECPPhesgo: <5
- EC-Pac/Carbo: 9
- FEC-50: <5
- Goserelin: <5
- Pac&Tras: <5
- Palbociclib: 32
- Pembro&PC/EC: <5
- Ribociclib: 42
- TucatCap Tras: <5
- Vinorel: <5
- WeeklyPacPhesgo: <5
- Zol Acid: 7
- Pembrolizumab subcutaneous injection: 0

2. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

Study Title	Recruited (org) Belfast Trust	Project site status 08/06/2026 - Belfast Trust
Modi-1 in Patients with Breast, Head & Neck, Ovarian or Renal Cancer: A Phase 1/2, Multicentre, Open-Label Study of Modi-1 in Patients with Breast, Head and Neck, Ovarian, or Renal Cancer	<5	Open
ATNEC–Axillary management in T1-3N1M0 breast cancer patients with FNA or core biopsy proven nodal metastases at presentation who convert to node negative after NEoadjuvant Chemotherapy	8	Open
EndoNET: Randomised controlled trial evaluating effectiveness of neoadjuvant endocrine treatment in post-menopausal women	<5	Open
FAST-Forward Boost: A randomised clinical trial testing a 1-week schedule of curative simultaneous integrated boost radiotherapy against a standard 3-week schedule in patients with early breast cancer	12	Open
The HER2-RADiCAL study (Response ADaptive CAre pLan) – Tailoring treatment for HER2 positive early breast cancer	<5	Open
LOLIPOP: Long-term Outcomes of Lidocaine Infusions for persistent Post-Operative Pain in patients undergoing breast surgery (LOLIPOP) Trial	15	Open

18 June 2026

SMALL: A Phase III, randomised, multi-centre trial addressing overtreatment of small screen-detected breast cancer by comparing standard surgery versus minimally invasive vacuum-assisted excision	41	Open
PHOENIX Trial: A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemotherapy resistant residual triple negative breast cancer	0	Open
REPOWER: "Real-world Evaluation of Patient Outcomes and Experiences with Ribociclib Early Adopters: A Hybrid Study with Prospective Patient-reported Outcomes and Retrospective Clinical Chart Review"	<5	Open

* Where numbers are low we have put <5 rather than state the actual figure. To ensure that patient remain non identifiable. Disclosure of this information would breach the first data protection principle, which relates to the fair and lawful processing of personal data. Therefore, we have concluded that this information is exempt from disclosure under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party.